Guanfacine for Hypertension and Adult ADHD

Primary FDA-Approved Indication: Hypertension

The American College of Cardiology and Hypertension guidelines suggest that guanfacine and other central alpha-2 agonists are generally reserved as last-line antihypertensives due to significant CNS adverse effects, especially in older adults 1, 2
The European Heart Journal recommends that central acting antihypertensives, such as guanfacine, may precipitate or exacerbate depression, bradycardia, and orthostatic hypotension in older adults (≥75 years) 3
The typical dose range for guanfacine in hypertension is 0.5-2 mg once daily, according to the Journal of the American College of Cardiology and Hypertension 1, 2
The American College of Cardiology and European Heart Journal emphasize that sudden cessation of guanfacine can produce a withdrawal syndrome with rebound hypertension, and the medication must be tapered rather than abruptly discontinued 1, 2, 3

The American Academy of Child and Adolescent Psychiatry and other guidelines suggest that guanfacine has medium effect sizes compared to placebo in adult ADHD, which are smaller than stimulants in head-to-head trials 4
The American Academy of Child and Adolescent Psychiatry recommends considering guanfacine for adult ADHD in first-line scenarios, such as comorbid substance use disorders, comorbid tic disorders or Tourette's syndrome, and significant sleep disturbances 4
The typical starting dose for guanfacine in adult ADHD is 1 mg once daily, with titration by 1 mg weekly based on response and tolerability, according to the American Academy of Child and Adolescent Psychiatry 4, 5
The American Academy of Child and Adolescent Psychiatry suggests that evening administration of guanfacine is strongly preferred to mitigate somnolence and fatigue, the most common adverse effects 4, 5

The European Heart Journal and American College of Cardiology recommend monitoring blood pressure and heart rate at baseline and during dose adjustments due to modest reductions in blood pressure and heart rate, which are common but rarely cause serious problems 4, 5
The American Academy of Child and Adolescent Psychiatry and European Heart Journal emphasize the importance of monitoring for hypotension/bradycardia and cardiac conduction abnormalities 4, 5

The American College of Cardiology, European Heart Journal, and American Academy of Child and Adolescent Psychiatry uniformly recommend tapering guanfacine by 1 mg every 3-7 days to avoid rebound hypertension and withdrawal syndrome 1, 2, 3, 4, 5